Literature DB >> 20018917

A novel Rag2-/-gammac-/--xenograft model of human CLL.

Maria Teresa Sabrina Bertilaccio1, Cristina Scielzo, Giorgia Simonetti, Maurilio Ponzoni, Benedetta Apollonio, Claudia Fazi, Lydia Scarfò, Martina Rocchi, Marta Muzio, Federico Caligaris-Cappio, Paolo Ghia.   

Abstract

Easily reproducible animal models that allow for study of the biology of chronic lymphocytic leukemia (CLL) and to test new therapeutic agents have been very difficult to establish. We have developed a novel transplantable xenograft murine model of CLL by engrafting the CLL cell line MEC1 into Rag2(-/-)gamma(c)(-/-) mice. These mice lack B, T, and natural killer (NK) cells, and, in contrast to nude mice that retain NK cells, appear to be optimal recipient for MEC1 cells, which were successfully transplanted through either subcutaneous or intravenous routes. The result is a novel in vivo model that has systemic involvement, develops very rapidly, allows the measurement of tumor burden, and has 100% engraftment efficiency. This model closely resembles aggressive human CLL and could be very useful for evaluating both the biologic basis of CLL growth and dissemination as well as the efficacy of new therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018917     DOI: 10.1182/blood-2009-05-223586

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia.

Authors:  Christopher J Ott; Alexander J Federation; Logan S Schwartz; Siddha Kasar; Josephine L Klitgaard; Romina Lenci; Qiyuan Li; Matthew Lawlor; Stacey M Fernandes; Amanda Souza; Donald Polaski; Deepti Gadi; Matthew L Freedman; Jennifer R Brown; James E Bradner
Journal:  Cancer Cell       Date:  2018-11-29       Impact factor: 31.743

2.  The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.

Authors:  Alba Matas-Céspedes; Anna Vidal-Crespo; Vanina Rodriguez; Neus Villamor; Julio Delgado; Eva Giné; Heleia Roca-Ho; Pablo Menéndez; Elías Campo; Armando López-Guillermo; Dolors Colomer; Gaël Roué; Adrian Wiestner; Paul W H I Parren; Parul Doshi; Jeroen Lammerts van Bueren; Patricia Pérez-Galán
Journal:  Clin Cancer Res       Date:  2016-09-16       Impact factor: 12.531

3.  A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.

Authors:  Davide Bagnara; Matthew S Kaufman; Carlo Calissano; Sonia Marsilio; Piers E M Patten; Rita Simone; Philip Chum; Xiao-Jie Yan; Steven L Allen; Jonathan E Kolitz; Sivasubramanian Baskar; Christoph Rader; Hakan Mellstedt; Hodjattallah Rabbani; Annette Lee; Peter K Gregersen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

4.  Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia.

Authors:  Priyanka Banerjee; Ronghua Zhang; Cristina Ivan; Giovanni Galletti; Karen Clise-Dwyer; Federica Barbaglio; Lydia Scarfò; Miguel Aracil; Christian Klein; William Wierda; William Plunkett; Federico Caligaris-Cappio; Varsha Gandhi; Michael J Keating; Maria Teresa S Bertilaccio
Journal:  Cancer Immunol Res       Date:  2019-09-17       Impact factor: 11.151

5.  Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts.

Authors:  Jerome Paggetti; Franziska Haderk; Martina Seiffert; Bassam Janji; Ute Distler; Wim Ammerlaan; Yeoun Jin Kim; Julien Adam; Peter Lichter; Eric Solary; Guy Berchem; Etienne Moussay
Journal:  Blood       Date:  2015-06-22       Impact factor: 22.113

6.  Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.

Authors:  Jian Yu; Liguang Chen; Bing Cui; George F Widhopf; Zhouxin Shen; Rongrong Wu; Ling Zhang; Suping Zhang; Steven P Briggs; Thomas J Kipps
Journal:  J Clin Invest       Date:  2016-02       Impact factor: 14.808

7.  In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.

Authors:  Greta Maria Paola Giordano Attianese; Virna Marin; Valentina Hoyos; Barbara Savoldo; Irene Pizzitola; Sarah Tettamanti; Valentina Agostoni; Matteo Parma; Maurilio Ponzoni; Maria T S Bertilaccio; Paolo Ghia; Andrea Biondi; Gianpietro Dotti; Ettore Biagi
Journal:  Blood       Date:  2011-03-15       Impact factor: 22.113

Review 8.  Antibody-based therapeutics for the treatment of human B cell malignancies.

Authors:  Sivasubramanian Baskar; Natarajan Muthusamy
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

Review 9.  Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.

Authors:  Yair Herishanu; Ben-Zion Katz; Andrew Lipsky; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2013-04       Impact factor: 3.722

Review 10.  Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade.

Authors:  Sarah E M Herman; Adrian Wiestner
Journal:  Semin Oncol       Date:  2016-02-08       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.